Table 5.
Ten-year outcomes by antibodies to self-antigens status
| Outcome | FN/Col-IV Abs+ (n=16) | FN/Col-IV Abs− (n=24) | P Value |
|---|---|---|---|
| Triple composite outcome, n (%) | 8 (50) | 7 (29) | 0.18 |
| Acute rejection, n (%) | 6 (38) | 2 (8) | 0.02 |
| Death with a functioning allograft, n (%) | 1 (6) | 5 (21) | 0.21 |
| Graft loss, n (%) | 6 (38) | 7 (29) | 0.58 |
| Death-censored graft loss, n (%) | 5 (31) | 2 (8) | 0.06 |
| Serum creatinine, mg/dla | 1.5±0.3 | 1.4±0.7 | 0.86 |
| eGFR, ml/min per 1.73m2a | 51±15 | 58±21 | 0.37 |
| UPC>0.5, n (%)b | 7 of 15 (47) | 5 of 19 (26) | 0.22 |
Comparison of 10-year outcomes between subjects who developed antibodies to self-antigens FN and Col-IV (FN/Col-IV Abs+) and those who remained FN/Col-IV antibody negative (FN/Col-IV Abs−) during year-1 post-transplant. The triple composite outcome is acute rejection, graft loss, or death with a functioning allograft. Of the six acute rejection episodes in the FN/Col-IV Abs+ group, one was early (<1 year post-transplant), four were intermediate (between 1 and 5 years post-transplant) and one was late (>5 years post-transplant). Of the two acute rejection episodes in the FN/Col-IV Abs− group, one was early and one was intermediate. Normally distributed continuous variables were compared using paired t test and are presented as mean±SD. Categoric variables were compared using Pearson chi-squared test or Fisher exact test where appropriate. UPC, urine protein-to-creatinine ratio.
Data on serum creatinine and eGFR are from 25 subjects (nine from FN/Col-IV Abs+ group and 16 from FN/Col-IV Abs− group) who remained alive with functioning allografts and had available data at 10 years post-transplant.
Data on UPC represent the maximum documented ratio in the medical record up to 10 years post-transplant in the 34 subjects in whom at least one data point was available.